UCB (OTCMKTS:UCBJF) Shares Gap Down – What’s Next?

Shares of UCB SA (OTCMKTS:UCBJF) gapped down prior to trading on Thursday . The stock had previously closed at $280.4875, but opened at $259.59. UCB shares last traded at $259.59, with a volume of 50 shares.

Analyst Upgrades and Downgrades

Separately, Piper Sandler reiterated a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, UCB has an average rating of “Moderate Buy”.

UCB Stock Performance

The firm’s fifty day moving average is $292.34 and its 200-day moving average is $300.05. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.